Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Basentabs pH-balance is a nutritional supplement developed by Pascoe Pharmazeutische Präparate designed to support the body's acid-base balance. Formulated as an oral tablet, it contains a combination of alkaline mineral salts, including calcium carbonate, magnesium carbonate, sodium bicarbonate, sodium phosphate, and potassium bicarbonate, along with zinc. The product is characterized by a 3:1 calcium-to-magnesium ratio. Zinc serves as a key functional ingredient that contributes to normal acid-base metabolism, likely by acting as a cofactor for enzymes such as carbonic anhydrase. The alkaline salts function to neutralize metabolic acids, thereby supporting physiological pH levels. It is indicated for individuals whose dietary habits, lifestyle factors, or physical activities may increase metabolic acid load, and it also supports bone health, muscle function, and energy metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Basentabs pH-balance.